Not intended for UK or U.S. based media Darmstadt, Germany (ots/PRNewswire) - - Company to present 16 abstracts on MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib at the 5th Congress of the European Academy of Neurology - Presentations include new data on the long-term efficacy and safety of MAVENCLAD®, new safety data for Rebif® and the 48-week analysis from the Phase 2 ...
San Francisco (ots/PRNewswire) - Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The primary endpoint was defined as ...
APR Applied Pharma Research s.a.
Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma Research sa (APR) presented at the recent 29th conference of the European Wound Management Association (EWMA) in Göteborg, the results of a clinical study confirming Nexodyn® AcidOxidizing Solution (AOS) to promote the restart of the healing process in ...
Amsterdam (ots/PRNewswire) - - Rifaximin significantly reduced the incidence of all-cause hospital admissions in HE patients with advanced cirrhosis on the waiting list for liver transplantation - Rifaximin contributed to improved outcomes in HE patients on the waiting list helping patients stay out of hospital for ...
Abstracts 54-OR and 55-OR Secondary data at 52 weeks demonstrated statistically significant blood sugar reductions and statistically significant reduction of body weight vs both Jardiance® and Victoza® San Francisco (ots/PRNewswire) - Findings presented today from two phase 3a clinical trials evaluated oral ...
Geneva (ots) - If they want to win, elite and amateur athletes need to make their oral health a top priority. FDI World Dental Federation (FDI) couldn't agree more. Today the organization released a series of sports dentistry resources for amateur and elite athletes, dentists and sports medicine physicians, and sports organizations. The release coincides with a packed ...
ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media Darmstadt, Germany (ots/PRNewswire) - - Alterations of the MET signaling pathway are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis - New interim data from Phase II ...
- Easy to measure biomarkers could identify a group of patients who benefit even more from ACARIZAX® treatment of house dust mite (HDM)-induced allergic asthma - Early identification of patients would allow earlier treatment intervention - With its HDM SLIT-tablet, ALK is well-placed to lead the way on ...
Prague (ots/PRNewswire) - Zentiva Group a.s. announces the completion of its previously declared acquisition of Romanian-based pharmaceutical company Solacium Pharma, together with its subsidiary, Be Well Pharma. The finalization of this acquisition will play a key role in the long-term growth strategy of Zentiva and will help to better support Romanian consumers' healthcare needs. About Zentiva Zentiva is a European ...
Not intended for media in the UK and the U.S. - Company launches global art campaign for people with MS to express their invisible symptoms and the unseen impact of the disease - Thought-provoking campaign coincides with the launch of MSonyourterms.com (http://www.msonmyterms.com/), a resource for patients, carers, and the public to understand MS from the Inside Out - Merck to donate EUR1 to the Multiple Sclerosis ...
Lausanne, Switzerland (ots) - First patient enrolled in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors Debiopharm (www.debiopharm.com) announced today the first patient enrolled in SMARTPLUS-106, an exploratory study investigating the safety and efficacy of ...
EUR62M funding will be used to progress wholly-owned pipeline products through clinical development and expand manufacturing activities Dr. Guido Guidi, Dr. Roberto Ferraresi and Dr. Roberto Marsella join the board of directors Siena, Italy (ots/PRNewswire) - Philogen S.p.A (or the "Company"), a clinical-stage biotechnology company focused on antibody-based therapeutics, today is pleased to announce a EUR62 million ...
Schweizerischer Nationalfonds / Fonds national suisse
Bern (ots) - A study funded by the SNSF shows that in winter, weak sunlight prevents the Swiss population from producing sufficient levels of vitamin D. Too much sun increases the risk of skin cancer. But moderate exposure is required to produce vitamin D. This substance is essential for bone health and may also play a role in preventing respiratory infections, autoimmune diseases and certain types of cancer. A new study ...
Not intended for U.S. or U.K. based media - 20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate Merck's commitment and clinical development program in multiple sclerosis Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that data from ...
issuer: Marinomed Biotech AG Veterinärplatz 1 A-1210 Wien phone: 0043250774460 FAX: 0043250774493 mail: office@marinomed.com WWW: www.marinomed.com ISIN: ATMARINOMED6, AT0000A1WD52 indexes: stockmarkets: Wien language: English ...
As part of its ongoing commitment to raising awareness of rosacea and the hidden burden of the disease, Galderma is collaborating with top social media influencers this Rosacea Awareness Month, to encourage people with rosacea to speak up and share experiences of the beyond the visible impact of living with this ...
- Rifaximin-a in combination with lactulose, the standard of care (SOC) treatment resulted in significant reductions ...
- Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis in the liver - Bempedoic acid significantly reduced LDL-Cholesterol (LDL-C) vs placebo at week 12 (primary endpoint, absolute reduction -36mg/dL, -21,4%) - Over 24-weeks, bempedoic acid was ...
- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's unique mechanism may provide an important new option for patients with ongoing active disease - MAVENCLAD demonstrated significant efficacy across key measures of disease activity ...
THE HAGUE, Netherlands (ots) - Dutch biotechnology company Micreos announced it has secured EUR30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its ...
FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future treatment option in this area of significant ...
FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY - Study will enrol 200 adult patients with limb trauma who are rescued by helicopter - Efficacy, tolerability and practicality of use of the inhaled analgesic in hostile mountain environments to be investigated Cambridge, England (ots/PRNewswire) - The Mundipharma network ...
EUR50,000 award goes to Newcastle University, in collaboration with Medical University, Graz and Newcastle Hospitals NHS Foundation Trust Staines-Upon-Thames, England (ots/PRNewswire) - Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the recipient of 2019's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation ...
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...
New Orleans (ots/PRNewswire) - Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia® (sitagliptin 100 mg). Non-inferiority for oral semaglutide 3 mg for HbA1c reductions at 26 weeks was not confirmed. Presented today at the Endocrine Society Annual Meeting in ...
Québec, Canada (ots) - GenePOC Inc., member of the Debiopharm Group, announces its third test to be cleared by the FDA, the GenePOC Strep A assay, to be used with the revogene(TM) device. About Group A Streptococcus (GAS) infection GAS is the most common bacterial etiology of pharyngitis accounting for 15 to 30% cases in children and 5 to 20% in adults[1]. In the ...
Paris and Zug, Switzerland (ots/PRNewswire) - Nordic Group, a pharmaceutical company focusing on the development and commercialisation of hospital and orphan products, and Primex Pharmaceuticals AG, an innovative global Anaesthesia pharmaceutical company, announced a strategic agreement today to launch OZALIN® in ...